secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001193125-23-139104
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health reports Shield test 83% sensitivity, 90% specificity for CRC in ECLIPSE study at DDW
--------------------------------------------------------------------------------

- Shield blood test achieved 83% overall sensitivity and 90% specificity in detecting colorectal cancer in average-risk adults.
- Sensitivity of 55% for Stage I, 100% for Stages II, III, and IV; 81% for Stages I-III, 72% for localized (Stage I-II).
- Real-world adherence rate for Shield exceeds 90% since commercial launch in May 2022.
- Study enrolled diverse population: 13% Black, 15% Hispanic, 7% Asian American.
- Data suggests Shield could detect CRCs at curable stage and help close screening gap.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000119312523139104/0001193125-23-139104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000119312523139104/d130904d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-139104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer